Glecaprevir/Pibrentasvir for the Treatment of PTSD
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct
acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD)
symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection
(HCV).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
White River Junction Veterans Affairs Medical Center